TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced prostate cancer~* Indication to initiate androgen deprivation therapy (ADT)~* Predefined cardiovascular disease~Exclusion Criteria:~* Previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial)~* Acute cardiovascular disease in the previous 30 days

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix (Type: EXPERIMENTAL): None
- Leuprolide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ranges from 18 to 70 years inclusive~* Essential hypertension~* Office Systolic BP (SBP) ≥ 150 mmHg or Diastolic BP (DBP) ≥ 90mmHg~* 3 or more anti-hypertensive medications of different classes, including a diuretic, or documented intolerance to multiple medications~* Type 2 Diabetes Mellitus on oral hypoglycaemic agent (OHA)~* 2 functional kidneys; eGFR ≥ 45 mL/min/1.73m² (MDRD formula)~* Suitable renal anatomy compatible with the endovascular denervation procedure~Exclusion Criteria:~* Individual has renal artery anatomy that is ineligible for treatment including:~* Patients with secondary hypertension~* Myocardial infarction, unstable angina pectoris, cerebrovascular accident within 6 months~* Patient with type 1 diabetes mellitus~* Patient on insulin due to oral drug failure~* Renovascular abnormalities (including severe renal artery stenosis, previous renal stenting or angioplasty, or known dual renal arteries)~* Pregnancy~* Patient with any implantable device incompatible with radiofrequency energy delivery~* Hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous~* Any serious medical condition, which in the opinion of the investigator, may limit the life expectancy of patients or adversely

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Renal denervation therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified breast cancer~* Large (≥ 3 cm) breast cancer~* IIb-IIIa stage~* ECOG (Eastern Cooperative Oncology Group) status: 0-1-2~* Adequate bone marrow reserve: (Haemoglobin ≥ 12g/l, Absolute Neutrophil Count (ANC) ≥ 2.0x 10\^9, Platelets ≥100 000)~* Laboratory results:~* Bilirubin ≤ Upper Limit Normal (ULN)~* Serum Glutamate Pyruvate Transaminase (SGPT) ≤ 2.5 ULN, Serum Glutamate Oxaloacetate Transaminase (SGOT) ≤ 2.5 ULN,~* Alk.phosph. ≤ 5.0 ULN,~* Creatinin ≤ ULN, if borderline calculated at ≤ 60ml/min~* Normal cardiac function (the result of Left Ventricular Ejection Function (LVEF) must be above the lower limit of normal for the institution)~* Negative pregnancy test~* Hormonal receptor status assessed~Exclusion Criteria:~* Pregnancy or lactation~* SGOT and/or SGPT \> 1.5 upper limit normal, associated with Alk.phosph \> 2.5 ULN~* Serious medical condition including but not limited to:~* Uncontrolled hypertension~* Active ulcus pepticum~* Non-stable diabetes mellitus~* Other contraindication of steroid treatment~* Myocardial infarction within the last 6 months prior study entry~* Significant neurologic/psychiatric disorders~* Active infection~* Peripheral neuropathy grade ≥ 2~* Unstable angina~* Severe arrhythmia~* Participation in other clinical trial~* Prior surgery, chemotherapy, hormonotherapy for breast cancer~* Past or current history of neoplasm other than breast cancer, except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 7 years~* History of hypersensitivity to the investigational products or to drugs with similar chemical structures~* Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol~* Treatment with any investigational product in the last 1 month before study entry.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Left Bundle Branch Block ECG Characteristics in the Evaluation of Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older~* LBBB on ECG~* Presenting to the ED and being evaluated for ACS~Exclusion Criteria:~* Prisoners~* Institutionalized individuals~* Patients who are incapable of giving legally effective consent~* Patients who cannot understand spoken English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with LBBB being evaluated for ACS (Type: None): Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Malaria Prevention Cambodia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Volunteer 18-65 years of age~2. Able to give informed consent~3. Likely to reside in malaria endemic area for the duration of the study~4. Available for follow-up for anticipated study duration, and agrees to participate for the duration of the study~5. Agrees not to seek outside medical care for febrile illness, except in emergency situations, unless referred by study team~6. Authorized by local commander to participate in the study if on active duty~Exclusion Criteria:~1. Known allergy or other contraindication to DHA, piperaquine treatment, and/or primaquine treatment~2. Significant acute comorbidity requiring urgent medical intervention~3. Positive malaria blood smear.~4. Treatment with an antimalarial drug in the past 30 days.~5. Pregnant or lactating female or a female of childbearing age who does not agree to use a highly effective method of birth control during the study~6. Significantly abnormal EKG including a QTcF interval greater than 450ms at baseline (or 470ms for females) using Fridericia's correction~7. Regular current use of known QTc prolonging medications~8. History of sudden cardiac death in an immediate family member, or personal history of known symptomatic coronary artery disease or arrhythmias~9. Judged by the investigator to be otherwise unsuitable for study participation or non-compliant with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- DHA-piperaquine (Type: EXPERIMENTAL): DHA-piperaquine monthly 2 day treatment course
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide informed consent and comply with all study requirements~* Age ≥ 40 years of age~* Stable, symptomatic heart failure with preserved ejection fraction and a H2FpEF Score ≥4~* Presence of non-malignant inferior vena cava obstruction, a unilateral or bilateral chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter defined by screening MRV, CTV and confirmed by a 50% reduction in luminal area as assessed by intraprocedural IVUS.~* Previous (\>6 months) history of ilio-femoral and/or lower extremity deep venous thrombosis associated with a residual ilio-femoral venous obstruction ≥50% by MRV, CTV.~* Clinically significant venous obstruction meeting CEAP Clinical classification ≥3.~* Negative pregnancy test in females of child-bearing potential~Exclusion Criteria:~* Subject hospitalized for acute compensated heart failure within 60 days prior to enrollment~* Presence of history of clinically significant pulmonary emboli within 6 months prior to enrollment.~* Subject has any permanent neurologic defect that may cause non-compliance with the protocol~* Subject has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous).~* Subject has an allergy to contrast media that cannot be adequately pre-treated prior to the required diagnostic and/or endovascular procedures.~* Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.~* Subject has renal failure or chronic kidney disease with glomerular filtration rate (GFR) ≤ 30 mL/min or Modification of Diet in Renal Disease (MDRD) study equation result of ≤ 30 mL/min per 1.73 m2.~* Subject has white blood cell (WBC) count \< 3.0 (3000 cells/mm3) within 7 days prior to index procedure.~* Subject has a platelet count \< 80,000 cells/mm3 or \> 700,000 cells/mm3 ≤ 7 days pre procedure; uncorrected hemoglobin of ≤9 g/dL.~* Subject has known or suspected active systemic infection evidenced by WBC \> 14.0 (14,000/mm3).~* Subject is currently participating in another investigational drug or device study.~* Subject intends to participate in another investigational drug or device study within 30 days after the index procedure.~* Subject has moderate or severe pulmonary disease (i.e., COPD) considered by Investigator to be a major contributing factor to the subject's exertional dyspnea

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Chair Sitting Exercise in Mechanically Ventilated Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute respiratory failure~* Requiring mechanical ventilation for more than 48 h~* Informed consent~Exclusion Criteria:~* Body mass index \> 40 kg/m2~* Severe neuropathy~* Hemodynamic instability, acute cor pulmonary embolism, acute myocardial ischemia/necrosis, hypoxemia~* Deep sedation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Standard group (Type: NO_INTERVENTION): None
- Chair sitting group (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unresectable pancreatic adenocarcinoma~* Weight loss of greater than 5% in the previous 6 months~* Life expectancy of greater than 3 months and a Karnofsky performance score of 60 or more.~* Non-smokers~Exclusion Criteria:~* Chemotherapy other than gemcitabine~* Radiotherapy, or surgical treatment in the previous month~* Consumption of dietary supplements or medications such as steroids that could affect metabolism.~* Presence of ascites~* Liver function test \> 2 standard deviation of upper limit~* Chronic or acute renal insufficiency~* Severe anemia with hemoglobin\<10~* Uncontrolled pain~* Uncontrolled nausea and vomiting~* Participation in a therapeutic research study within 30 days of baseline~* Diet restrictions including vegetarianism and veganism~* Allergy or intolerance to fish and/or fish oil

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diet + Nutrawell Powder with Fish Oil (Type: ACTIVE_COMPARATOR): Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
- Dietary Intervention Only (Type: ACTIVE_COMPARATOR): Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥40 (to reduce the likelihood of enrolling patients with obstruction due to primary sclerosing cholangitis)~2. Cholestatic liver function tests, including serum alkaline phosphatase level ≥ 300 IU/L and bilirubin level ≥ 3.7 mg/dL~3. Radiographic evidence of a biliary hilar stricture OR intrahepatic but no extrahepatic biliary ductal dilation~Exclusion Criteria:~1. Known radiographic evidence of a Bismuth-Corlette type 1 biliary stricture~2. Known diagnosis of primary sclerosing cholangitis without suspicion of dominant hilar stricture~3. Recent gallbladder/biliary surgery within 12 months~4. Known Mirizzi syndrome~5. Known IgG4-mediated cholangiopathy~6. Significant liver metastatic disease interfering with safe/effective PTBD~7. Significant ascites interfering with safe/effective PTBD~8. Known regional malignant-appearing adenopathy or extra-biliary mass, indicating the need for concurrent EUS-FNA~9. Prior ERCP or PTBD for hilar obstruction~10. Surgically altered luminal anatomy other than prior Billroth reconstruction or Whipple resection~11. Standard general contraindications to ERCP or PTBD (e.g. hemodynamic instability, uncorrected coagulopathy, etc.)~12. Inability or unwillingness to follow study protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Percutaneous Transhepatic Drainage (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
- Endoscopic Retrograde Cholangiography (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will undergo ERC as the first drainage intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be at least 18 years old.~2. Patient must have a terminal diagnosis, with estimated survival of 6 months or less.~3. Patients must have nausea and/or vomiting, not relieved with 1 or more anti-nausea medications. If the patient is treated with an anti-nausea medication, a minimum of 2 hours should pass to ensure that the medication is given a chance to be effective. If there is no relief after 2 hours, then the patient may be treated with palonosetron.~4. Patient's medications must be reviewed. Any medications possibly causing nausea should be stopped if possible. For example, if an opiate is suspected of causing nausea, another opiate should be substituted. However, if this is not effective, or if a medication change cannot be made, then the patient would be eligible for this study.~5. Patient must be able to understand and sign informed consent~6. Patients who have a bowel obstruction that will not be relieved by surgery may be enrolled. This includes patients whose obstruction is technically unresectable, or who are medically too ill to endure a surgery, or who refuse surgical intervention for any reason~Exclusion Criteria:~1. Patient has received chemotherapy in the past 28 days.~2. Assessment of possible causes of the nausea and vomiting should be done and recorded. If a reversible cause of the nausea is identified, that cause should be treated if possible. If the treatment relieves the nausea, then the patient is excluded from this study. Possible reversible causes of nausea and vomiting that should be excluded are:~   * Other medical conditions such as benign positional vertigo, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palonosetron (Type: EXPERIMENTAL): Palonosetron 0.25 mg I.V. bolus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with stage IV, pathologically confirmed, NSCLC not suitable for/declining/not tolerating 1st/2nd-line palliative chemotherapy, or following completion of 1st/2nd-line palliative chemotherapy~* A likely prognosis of ≥3 months.~* Cachexia on the basis of any of the following, weight loss \>5% over past 6 months, or BMI \<20kg/m2 and weight loss \>2%, or appendicular skeletal muscle index determined by duel energy x-ray absorptiometry consistent with sarcopenia and weight loss \>2%.~* Systemic inflammation on the basis of a C-reactive protein \>10mg/L.~* Adequate renal function as defined by creatinine ≤132micromol/L and eGFR ≥30mL/min/1.73m2~* Adequate liver function as defined by the following parameters, bilirubin ≤25micromol/L, and AST and ALT ≤2 times upper limit of normal, unless liver metastases, in which case ≤5 times upper limit of normal~* Prepared to suspend, if necessary, the use of certain statins and/or substitute the use of domperidone for an alternative anti-emetic for the duration of the study~Exclusion Criteria:~* ECOG Performance Status 3 or 4~* Little or no food intake~* Weight loss \>10% in 1 month or \>20% in total~* Known hypersensitivity to clarithromycin~* Inability to accurately measure QT interval, e.g. atrial fibrillation~* QTc prolongation \>450 milliseconds in a male, or 470 milliseconds in a female~* History of ventricular arrhythmia~* Severe cardiac insufficiency (NYHA class \>2)~* Untreated hypokalaemia/hypomagnesaemia~* Active infection requiring antibiotics~* Current or recent (within last 4 weeks) history of Clostridium difficile, eating disorder, dysphagia, malabsorption or diarrhoea~* Untreated adrenal or thyroid diseases~* Brain metastases~* Use of corticosteroids/progestogens~* Use of chemotherapy, other immunosuppressive, or antiviral (e.g. hepatitis C, HIV) drugs within 4 weeks~* Drugs which are contra-indicated (except certain statins which can be temporarily suspended and domperidone which can be substituted for an alternative anti-emetic) or should be avoided in patients receiving clarithromycin, either because of the risk of a drug-drug interaction and/or prolonged QT~* Pregnancy~* Breast Feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clarithromycin (Type: ACTIVE_COMPARATOR): Clarithromycin 250mg by mouth twice a day for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched capsule one capsule by mouth twice a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility